BRCA2 and acute myeloid leukemia: Only patients PMCFANC02 (FANCD1/BRCA2) and IBFM35 (FANCA and AML) had a significantly increased indel burden compared to healthy HSPCs (also in their bulk-sequenced clones and leukemic blasts) (Figures 4A, 4B, and S9C).